{"id":23531,"date":"2025-04-13T17:39:56","date_gmt":"2025-04-13T17:39:56","guid":{"rendered":"https:\/\/researchchemicalstore.eu\/?post_type=product&p=23531"},"modified":"2025-10-22T16:39:51","modified_gmt":"2025-10-22T16:39:51","slug":"ept-fumaraat-n-etuul-n-propuul-truptamiin","status":"publish","type":"product","link":"https:\/\/researchchemicalstore.eu\/et\/product\/ept-fumaraat-n-etuul-n-propuul-truptamiin\/","title":{"rendered":"EPT fumaraat (N-et\u00fc\u00fcl-N-prop\u00fc\u00fcltr\u00fcptamiin)"},"content":{"rendered":"

EPT fumaraat (N-et\u00fc\u00fcl-N-prop\u00fc\u00fcltr\u00fcptamiin) \u2013 teaduslik tootekirjeldus<\/span><\/span><\/strong><\/h3>\n

\u00dcldised omadused<\/span><\/span><\/strong><\/h4>\n

EPT fumaraat on tr\u00fcptamiinide klassi kuuluv uurimiskemikaal, mida iseloomustab ainulaadne N-et\u00fc\u00fcl-N-prop\u00fc\u00fcli asendusmuster. See \u00fchend sarnaneb struktuurilt tuntud tr\u00fcptamiinidega nagu DMT ja MET, kuid eristub spetsiifiliste farmakod\u00fcnaamiliste omaduste poolest.<\/span><\/span><\/p>\n

P\u00f5hispetsifikatsioonid:<\/span><\/span><\/strong><\/p>\n

    \n
  • \n

    Keemiline puhtus:<\/span><\/span><\/strong> \u00a0>98% (kontrollitud HPLC-MS abil)<\/span><\/span><\/p>\n<\/li>\n

  • \n

    Molekulaarne stabiilsus:<\/span><\/span><\/strong> \u00a0Suurep\u00e4rane stabiilsus t\u00e4nu fumaraatsoola moodustumisele<\/span><\/span><\/p>\n<\/li>\n

  • \n

    Lahustuvus:<\/span><\/span><\/strong> \u00a0Vees ja orgaanilistes lahustites h\u00e4sti lahustuv<\/span><\/span><\/p>\n<\/li>\n

  • \n

    S\u00e4ilitamistingimused:<\/span><\/span><\/strong> \u00a0Pikaajaline stabiilsus temperatuuril -20\u00b0C inertgaasi atmosf\u00e4\u00e4ris<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

    Teaduslikud rakendused<\/span><\/span><\/strong><\/h4>\n
      \n
    1. \n

      Neurofarmakoloogilised uuringud:<\/span><\/span><\/strong><\/p>\n

        \n
      • \n

        Serotonergiliste retseptorite koostoimed (5-HT1A\/2A\/2C)<\/span><\/span><\/p>\n<\/li>\n

      • \n

        Monoamiinoks\u00fcdaasi inhibeerimise uuringud<\/span><\/span><\/p>\n<\/li>\n

      • \n

        Neurotransmitterite vabanemise mehhanismid<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

      • \n

        Ainevahetusuuringud:<\/span><\/span><\/strong><\/p>\n

          \n
        • \n

          Maksa mikrosoomide metabolismi profiil<\/span><\/span><\/p>\n<\/li>\n

        • \n

          Ts\u00fctokroom P450 interaktsiooni anal\u00fc\u00fcs<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

        • \n

          V\u00f5rdlev farmakoloogia:<\/span><\/span><\/strong><\/p>\n

            \n
          • \n

            Struktuuri ja aktiivsuse seosed v\u00f5rreldes teiste N,N-dialk\u00fc\u00fcltr\u00fcptamiinidega<\/span><\/span><\/p>\n<\/li>\n

          • \n

            Annuse-vastuse iseloomustus in vitro<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

            Katsejuhised<\/span><\/span><\/strong><\/h4>\n

            In vitro uuringute annusvahemikud:<\/span><\/span><\/strong><\/p>\n

            \n\n\n\n\n\n\n\n
            Taotlus<\/span><\/span><\/th>\nKontsentratsioonivahemik<\/span><\/span><\/th>\nOptimaalne inkubatsiooniperiood<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n
            Retseptori sidumine<\/span><\/span><\/td>\n10 nM \u2013 1 \u03bcM<\/span><\/span><\/td>\n30\u201360 minutit<\/span><\/span><\/td>\n<\/tr>\n
            Ainevahetuse uuringud<\/span><\/span><\/td>\n1\u2013100 \u03bcM<\/span><\/span><\/td>\n2\u20134 tundi<\/span><\/span><\/td>\n<\/tr>\n
            Rakkude toksilisus<\/span><\/span><\/td>\n10\u2013500 \u03bcM<\/span><\/span><\/td>\n24\u201348 tundi<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

            Ohutusprotokollid:<\/span><\/span><\/strong><\/p>\n

              \n
            • \n

              T\u00f6\u00f6tage alati kontrollitud laboritingimustes<\/span><\/span><\/p>\n<\/li>\n

            • \n

              N\u00f5utavad isikukaitsevahendid (laborikittel, nitriilkindad, kaitseprillid)<\/span><\/span><\/p>\n<\/li>\n

            • \n

              Lahustitega t\u00f6\u00f6tamisel kasutage ainult t\u00f5mbekappi.<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

              Stabiilsusandmed<\/span><\/span><\/strong><\/h4>\n

              Dokumenteeritud stabiilsus:<\/span><\/span><\/strong><\/p>\n

                \n
              • \n

                Toatemperatuur: <72 tundi lahuses<\/span><\/span><\/p>\n<\/li>\n

              • \n

                K\u00fclmkapis (4\u00b0C): stabiilne 1 n\u00e4dal<\/span><\/span><\/p>\n<\/li>\n

              • \n

                K\u00fclmutatud (-20\u00b0C): stabiilne >6 kuud<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                Soovitatav hoiustamine:<\/span><\/span><\/strong><\/p>\n

                  \n
                • \n

                  Esmane pakend: Merevaikklaasist viaalid PTFE korgiga<\/span><\/span><\/p>\n<\/li>\n

                • \n

                  Teisene pakend: vaakumpakendis silikageeliga<\/span><\/span><\/p>\n<\/li>\n

                • \n

                  S\u00e4ilitamistingimused: -20\u00b0C argooniatmosf\u00e4\u00e4ris<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                  Anal\u00fc\u00fctiline sertifitseerimine<\/span><\/span><\/strong><\/h4>\n

                  Iga partiiga on kaasas:<\/span><\/span><\/p>\n

                    \n
                  1. \n

                    Ulatuslik HPLC anal\u00fc\u00fcs (UV\/VIS tuvastamine)<\/span><\/span><\/p>\n<\/li>\n

                  2. \n

                    Massispektromeetria kinnitus (LC-MS\/MS)<\/span><\/span><\/p>\n<\/li>\n

                  3. \n

                    J\u00e4\u00e4nud lahusti anal\u00fc\u00fcs<\/span><\/span><\/p>\n<\/li>\n

                  4. \n

                    Veesisalduse m\u00e4\u00e4ramine (Karl Fischer)<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n

                    \u00d5iguslik staatus ja eetika<\/span><\/span><\/strong><\/h4>\n

                    Hollandi eeskirjad:<\/span><\/span><\/strong><\/p>\n

                      \n
                    • \n

                      Praegu ei kuulu oopiumiseadusse<\/span><\/span><\/p>\n<\/li>\n

                    • \n

                      Kehtib uurimiskemikaalide puhul ravimite \u00fcld\u00f5igusaktide alusel<\/span><\/span><\/p>\n<\/li>\n

                    • \n

                      Teadusasutuste kohustuslik registreerimine<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                      Eetikajuhised:<\/span><\/span><\/strong><\/p>\n

                        \n
                      • \n

                        Ainult mittekliiniliseks kasutamiseks<\/span><\/span><\/p>\n<\/li>\n

                      • \n

                        Keelatud manustada inimestele v\u00f5i loomadele<\/span><\/span><\/p>\n<\/li>\n

                      • \n

                        Akadeemilise uurimist\u00f6\u00f6 kohustuslik eetiline l\u00e4bivaatamine<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                        Korduma kippuvad k\u00fcsimused<\/span><\/span><\/strong><\/h4>\n

                        K1: Kuidas EPT v\u00f5rdub struktuurilt sarnaste tr\u00fcptamiinidega?<\/span><\/span><\/strong>
                        \n A: Et\u00fc\u00fclprop\u00fc\u00fcli asendus omab ainulaadseid farmakokineetilisi omadusi, eriti j\u00e4rgmistel juhtudel:<\/span><\/span><\/p>\n

                          \n
                        • \n

                          Lipofiilsuse profiil (logP v\u00e4\u00e4rtus: 2,1)<\/span><\/span><\/p>\n<\/li>\n

                        • \n

                          Valkude sidumisv\u00f5ime (88-92%)<\/span><\/span><\/p>\n<\/li>\n

                        • \n

                          Aju barj\u00e4\u00e4ri l\u00e4bitungimine (suhe DMT-ga 0,65)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                          K2: Millised on avastamisv\u00f5imalused tavap\u00e4raste narkos\u00f5eluuringute puhul?<\/span><\/span><\/strong>
                          \n A: EPT-d ei tuvastata tavap\u00e4raste immunoloogiliste testide abil, kuid see on tuvastatav j\u00e4rgmiste meetodite abil:<\/span><\/span><\/p>\n

                            \n
                          • \n

                            GC-MS (iseloomulik fragmentatsioon m\/z 130, 144 juures)<\/span><\/span><\/p>\n<\/li>\n

                          • \n

                            LC-QTOF (molekulaarmassi t\u00e4ppism\u00f5\u00f5tmine)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                            K3: Kas on teadaolevaid koostoimeid ravimitega?<\/span><\/span><\/strong>
                            \n A: Teoreetilised interaktsioonid on v\u00f5imalikud j\u00e4rgmistega:<\/span><\/span><\/p>\n

                              \n
                            • \n

                              MAO inhibiitorid (toime tugevnemine)<\/span><\/span><\/p>\n<\/li>\n

                            • \n

                              SSRI-d (konkureeriv inhibitsioon)<\/span><\/span><\/p>\n<\/li>\n

                            • \n

                              Antips\u00fchhootikumid (retseptorite konkurents)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                              K4: Milline on soovitatav j\u00e4\u00e4tmek\u00e4itlusviis?<\/span><\/span><\/strong>
                              \n A: J\u00e4rgige ohtlike j\u00e4\u00e4tmete protokolli:<\/span><\/span><\/p>\n

                                \n
                              • \n

                                Neutraliseerige lahjendatud vesinikkloriidhappega (0,1 M)<\/span><\/span><\/p>\n<\/li>\n

                              • \n

                                Imada sobiva materjaliga (nt vermikuliit)<\/span><\/span><\/p>\n<\/li>\n

                              • \n

                                H\u00e4vitage ohtliku keemilise j\u00e4\u00e4tmena (E\u00dc number: 404-860-3)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                                Teaduslikud viited<\/span><\/span><\/strong><\/h4>\n

                                Olulised kirjandusviited:<\/span><\/span><\/p>\n

                                  \n
                                1. \n

                                  Nichols, D. E. (2018). \u201cTr\u00fcptamiinide struktuuri ja aktiivsuse seosed\u201d.\u201d<\/span><\/span><\/p>\n<\/li>\n

                                2. \n

                                  Brandt jt (2020). \u201eUute ps\u00fchhoaktiivsete ainete anal\u00fc\u00fctiline iseloomustus\u201c<\/span><\/span><\/p>\n<\/li>\n

                                3. \n

                                  ELi varajase hoiatamise s\u00fcsteem (2023). \u201eUute tr\u00fcptamiini derivaatide riskihindamine\u201d.<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n

                                  See toode on m\u00f5eldud \u00fcksnes kvalifitseeritud personali poolt l\u00e4biviidavaks volitatud teaduslikuks uurimist\u00f6\u00f6ks. Kogu teave on esitatud ilma igasuguse kaudse garantiita. Kasutajad vastutavad kohalike eeskirjade j\u00e4rgimise eest.<\/span><\/span><\/em><\/p>","protected":false},"excerpt":{"rendered":"

                                  EPT fumarate properties<\/span><\/span><\/span><\/span><\/span><\/h3>\n

                                  Synonym:<\/span><\/span><\/span><\/span><\/strong> N-ethyl-N-propyltryptamine fumarate <\/span><\/span><\/span><\/span>
                                  \nCAS Number:<\/span><\/span><\/span><\/span><\/strong> n\/a <\/span><\/span><\/span><\/span>
                                  \nFormula:<\/span><\/span><\/span><\/span><\/strong> 3-[2-(ethyl(propyl)amino)ethyl]-1H-indole fumarate <\/span><\/span><\/span><\/span>
                                  \nMolar Mass:<\/span><\/span><\/span><\/span><\/strong> 346.4 g\/mol <\/span><\/span><\/span><\/span>
                                  \nPurity:<\/span><\/span><\/span><\/span><\/strong> >97%<\/span><\/span><\/span><\/span><\/p>\n","protected":false},"featured_media":28774,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[509,381],"product_tag":[326],"class_list":["post-23531","product","type-product","status-publish","has-post-thumbnail","product_cat-ept","product_cat-tryptamines","product_tag-nl","first","instock","taxable","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product\/23531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/comments?post=23531"}],"version-history":[{"count":5,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product\/23531\/revisions"}],"predecessor-version":[{"id":28071,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product\/23531\/revisions\/28071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/media\/28774"}],"wp:attachment":[{"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/media?parent=23531"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product_brand?post=23531"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product_cat?post=23531"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/researchchemicalstore.eu\/et\/wp-json\/wp\/v2\/product_tag?post=23531"}],"curies":[{"name":"t\u00f6\u00f6leht","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}